Recruitment for this study has ended, so applications are closed. You can still read the trial details, or browse similar trials that are currently recruiting.
Sponsor:
Merck Sharp & Dohme LLC
Code:
NCT07044297
Conditions
Human Immunodeficiency Virus (HIV)
HIV Pre-Exposure Prophylaxis
Eligibility Criteria
Sex: All
Age: 16+
Healthy Volunteers: Accepted
Interventions
MK-8527
FTC/TDF
Placebo to MK-8527
Placebo to FTC/TDF
Brief summary:
Conditions
Human Immunodeficiency Virus (HIV)
HIV Pre-Exposure Prophylaxis
Study ID
NCT07044297
Start date
Jul 31, 2025
Status verified date
Sep, 2026
Completion date
Jul 22, 2027
Anticipated
Primary completion date
Jul 22, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 16+
Healthy Volunteers: Accepted
Enrollment
4390 participants
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: MK-8527
active comparator: FTC/TDF
Interventions
MK-8527
FTC/TDF
Placebo to MK-8527
Placebo to FTC/TDF
Primary outcome measure
Sponsor
Merck Sharp & Dohme LLC
Last update posted
Sep 18, 2026
Last verified
Sep, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-12. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-09-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.